References

medalphabet

Медицинский алфавит

Medical alphabet

2078-56312949-2807

ООО «Альфмед»

medalphabet-265

Research Article

Статьи

Лекарственная терапия второй и последующих линий при раке желудка. Шаг вперед после долгих лет застоя?

Second and further lines of the therapy in metastatic gastric carcinoma. Step forward after stagnation years?

Трякин

А. А.

Tryakin

A. A.

noemail@neicon.ru

Федянин

М. Ю.

Fedyanin

M. U.

noemail@neicon.ru

ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава РоссииРоссияRussian Oncological Scientific Centre n.a. N.N. BlokhinRussian Federation

2017

14082017

225

Диагностика и онкотерапия

611

2017

Трякин А.А., Федянин М.Ю.

Tryakin A.A., Fedyanin M.U.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-alphabet.com/jour/article/view/265

В данной статье суммированы последние данные, касающиеся лекарственной терапии второй и последующих линий пациентов с метастатическим раком желудка. Рассматриваются различные варианты классической химиотерапии, а также таргетная терапия, в частности, анти-PD моноклональные антитела и рамуцирумаб, достоверно увеличивающие продолжительность жизни пациентов. Применение прогностических моделей, основанных на факторах риска, позволяет отбирать пациентов с наибольшим выигрышем от проведения терапии второй линии.

This article summarizes the latest data concerning second and later lines treatments of patients with metastatic gastric carcinoma. Different variants of classical chemotherapy as well as targeted therapy (anti-PD checkpoint inhibitors, ramucirumab) significantly improve overall survival. Risk models based on prognostic factors help to select patients with most benefit on second-line treatment.

рак желудкавторая линияхимиотерапиятаргетная терапияфакторы рискарамуцирумаб

stomach cancersecond linechemotherapytargeted therapyrisk factorsramucirumab

References1

Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Злокачественные новообразования в России в 2014 года (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИРЦ» Минздрава России, 2016. 250 с. ISBN 978-5-85502-219-3.

Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3; 358 (1): 36-46.

Kang Y.K., Kang W.K., Shin D.B., et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr; 20 (4): 666-73.

van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1; 24 (31): 4991-7.

Al-Batran S.E., Pauligk C., Homann N., et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesoph-agogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer (2013) 49, 835-842.

Shah M.A., Janjigian Y.Y., Stoller R., et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol. 2015 Nov 20; 33 (33): 3874-9.

Thuss-Patience P.C., Kretzschmar A., Bichev D., et al. Survival advantage for irinotecan versus best supportive care assecond-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer 47, 2306-2314.

Kang J.H., Lee S.I., Lim D.H., et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1; 30 (13): 1513-8.

Ford H.E., Marshall A., Bridgewater, et al. Docetaxel versus active symptom control for refracto-ryoesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014, 15, 78-86.

Kim H.S., Kim H.J., Kim S.Y., et al. Second-line chemotherapy versus supportive cancer treatment in advancedgastric cancer: a meta-analysis. Ann. Oncol. 2013, 24: 2850-2854.

Hironaka S., Ueda S., Yasui, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxelin patients with advanced gastric cancer without severe peritoneal metastasisafter failure of prior combination chemotherapy using fluoropyrimidine plus-platinum: WJOG 4007 trial. J Clin Oncol 2013, 31: 4438-4444.

Sym S.J., Hong J., Park J., et al. A randomized-phase II study of biweekly irinotecan monotherapy or a combination ofirinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients withmetastatic gastric adenocarcinoma refractory to or progressive after first-linechemotherapy. Cancer Chemother. Pharmacol. 2013, 71: 481-488.

Higuchi K., Tanabe S., Shimada, et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-linetreatment for advanced gastric cancer: a randomised phase III trial (TCOGGI-0801/BIRIP trial). Eur J Cancer 2014, 50: 1437-1445.

Tanabe K., Fujii M., Nishikawa K., et al. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol. 2015 Sep; 26 (9): 1916-22.

Guimbaud R., Louvet C., Ries P., et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine inadvanced gastric adenocarcinoma: a French intergroup study. J. Clin. Oncol. 2014, 32: 3520-3526.

Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER 2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28; 376 (9742): 687-97.

Ohtsu A., Ajan, J.A., Bai Y.X., et al. Everolimus for previously treated advanced gastric cancer: results of therandomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013, 31: 3935-3943.

Moehler M.H., Thuss-Patience P.C., Schmol H.J., et al. FOLFIRI plus sunitinib versus FOLFIRI alone inadvanced chemorefractory esophagogastric cancer patients: a randomizedplacebo-controlled multicentric AIO phase II trial. J. Clin. Oncol. 4086 (Suppl) (abstr4086).

Satoh T., Lee K.H., Rha S.Y., et al. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecanalone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer 2014, DOI 10.1007/s10120-014-0420-9.

Satoh T., Xu R.H., Chung H.C., et al. Lapatinibplus paclitaxel versus paclitaxel alone in the second-line treatment ofHER 2-amplified advanced gastric cancer in Asian populations: TyTAN-arandomized, phase III study. J Clin Oncol 2014, 32: 2039-2049.

Bang Y., Boku N., Chin K., et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD. Annals of Oncology (2016) 27 (6): 1-36.

Kang Y.K., Shah M., Ohtsu A., et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER 2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma. J Clin Oncol 34, 2016 (suppl 4S; abstr 5).

Li J., Qin S., Xu J., et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016 May 1; 34 (13): 1448-54.

Fuchs C.S., Tomasek J., Yong C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric orgastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014, 383: 31-39.

Wilke H., Muro K., Van Cutsem E., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients withpreviously treated advanced gastric or gastro-oesophageal junctionadenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014,15: 1224-1235.

Kang Y.K., Satoh T., Ryu M-H, et al. Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. J Clin Oncol 35, 2017 (suppl 4S; abstract 2).

Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011; 29: 3968-3976.

Shen L., Li J., Xu J., et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015 Jan; 18 (1): 168-76.

Van Cutsem E., de Haas S., Kang Y.K., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012 Jun 10; 30 (17): 2119-27.

Al-Batran S.E., Van Cutsem E., Oh S.C., et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol 2016; 27: 673-9.

Muro K., Cho J.K., Bodoky G., et al. Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials. J Clin Oncol, 2017, 35 (4) suppl (February) 3-3.

Büyükkaramikli N.C., Blommestein H.M., Riemsma R., et al. Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2017 Jun 27. doi: 10.1007/s40273-017-0528-y. [Epub ahead of print].

Pavlakis N., Sjoquist K.M., Tsobanis E., et al. INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG), first results. J Clin Oncol 33, 2015 (suppl 3; abstr 9).

Kang Y.-K., Satoh T., Ryu M.-H., et al. Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. J Clin Oncol 35, 2017 (suppl 4S; abstract 2).

Janjigian Y.Y., Ott P.A., Calvo E., et al. Nivolumab ± ipilimumab in pts with advanced (adv)/meta-static chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. Journal of Clinical Oncology 35, no. 15 suppl (May 2017) 4014-4014.

Kanagavel D., Pokataev I.A., Fedyanin M.Y., et al. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Annals of Oncology 2010, 21: 1779-1785.

Fanotto V., Cordio S., Pasquini G., et al. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer, 2017, 20 (5): 825-833.

Fuchs C., Muro K., Tomasek J., et al. Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. J Gastric Cancer. 2017 Jun; 17 (2): 132-144.

The authors declare that there are no conflicts of interest present.